



PARIS  
INTERNATIONAL  
LIVER MEETING

# SCIENTIFIC PROGRAM 2026

Maison de la Chimie, Paris  
January 19-21, 2026

1<sup>st</sup> annual meeting

With the scientific support of



## Welcome to the Paris International Liver Meeting 2026!

Dear Colleagues,

It is our great pleasure to welcome you on behalf of the Scientific Committee to the Paris International Liver Meeting, which will be held in the beautiful city of Paris from January 19-21, 2026.

This meeting will bring together leading experts, clinicians, researchers, biopharmaceutical industry and healthcare professionals from around the world to share the latest clinically relevant advances in the management and treatment of chronic liver diseases. Also, this meeting will bring together all important stakeholders to interact and share practical perspectives about important liver diseases.

Over three days, the program will explore and provide up-to-date short reviews by the best experts on the different aspects of clinical hepatology, including MASLD, MetALD, ALD, viral hepatitis, cholestatic liver diseases, HCC and complications of cirrhosis.

Over the course of the meeting, you will have the opportunity to interact with thought leaders, attend thought-provoking sessions, contribute to discussions and interact with leading biopharmaceutical leaders in liver disease that we hope will not only deepen your knowledge, but also be helpful in your clinical practice.

Join us at the prestigious Maison de la Chimie for a fruitful and productive meeting!

**Laurent Castera, MD PhD**

**Zobair M. Younossi, MD**

Co-Chairs, Paris International Liver Meeting





MONDAY, 19 JANUARY - MORNING

08:00 - 08:20 AM WELCOME DESK OPENING

08:20 - 08:30 AM INTRODUCTION

Laurent Castera (FR) & Zobair Younossi (US)

08:30 - 10:00 AM SESSION 1: Hepatitis B – D Optimal Management

Chairs: Pietro Lampertico (IT) & Sabela Lens (ES)

08:30-08:45 EASL/AASLD 2025 HBV guidelines Markus Cornberg (DE)

08:45-09:00 HDV new insights from virology to epidemiology and natural history Maurizia Brunetto (IT)

09:00-09:15 HDV therapy: BLV monotherapy and combination Tarik Asselah (FR)

09:15-09:30 HDV therapy: new antiviral therapies (phase 2 studies) Pietro Lampertico (IT)

09:30-10:00 Panel discussion (Moderator Sabela Lens)

10:00 - 11:00 AM Obesity in the Metabolic Era: Global Burden, Treatment, and Clinical Integration

Chairs: Laurent Castera (FR) & Zobair Younossi (US)

10:00-10:02 Opening Remarks Zobair Younossi (US)

10:02-10:12 Global Burden of Obesity and Associated Cardiometabolic Risks S. Zelber Sagi (IL)

10:12-10:27 Pharmacologic Treatment of Obesity John Wilding (UK)

10:27-10:42 Integrated Care Pathways for Obesity and Cardiometabolic Conditions: Creating the Metabolic Clinics Arya Sharma (CA)

10:42-11:00 Panel Discussion — Translating Evidence into Integrated Practice

Moderated by Laurent Castera (FR)

Faculty (S. Zelber Sagi, John Wilding, and Arya Sharma)



MONDAY, 19 JANUARY - MORNING

11:00 - 11:20 AM COFFEE BREAK

11:20 - 12:50 PM SESSION 2: Advances in the Management of Cirrhosis Complications

Chairs: Annalisa Berzigotti (CH) & Adrian Gadano (AR)

11:20-11:35	<b>What new evidence and definitions have been further developed with Baveno VII and beyond</b> Annalisa Berzigotti (CH)
11:35-11:50	<b>Transjugular intrahepatic porto-systemic shunt (TIPS): Expanding Indications and Refining Risk Stratification</b> Dominique Thabut (FR)
11:50-12:05	<b>Acute Kidney Injury in Cirrhosis: an update from the ADQI and International Club of Ascites (ICA) Consensus</b> Claire Francoz (FR)
12:05-12:20	<b>New challenges in SBP prophylaxis: Beyond the guidelines</b> Paolo Angeli (IT)
12:20-12:50	<b>Panel Discussion</b> (Moderator Adrian Gadano)



MONDAY, 19 JANUARY - AFTERNOON

01:00 - 02:00 PM WORKSHOPS

**1 - How do I use new HBV markers in practice?**

Jean-Michel Pawlotsky (FR) & Alessio Aghemo (IT)

**2 - How do I manage and treat HDV in my practice?**

Maria Buti (ES) & TBC

**3 - When should I consider liver transplantation in a patient with HCC?**

François Durand (FR) & Jean-François Dufour (CH)

**4 - MASLD and viral hepatitis (hepatitis B & C): is there an impact?**

George Papatheodoridis (GR) & Yusuf Yilmaz (TR)

**5 - How do I use NITs for treatment of MASH in 2026?**

Vlad Ratziu (FR) & Vincent Wong (HK)

02:00 - 02:30 PM COFFEE / DESSERTS

02:30 - 03:00 PM STATE OF THE ART LECTURE

Chair : Lawrence Serfaty (FR)

**Fibrosis in MASH: A Surrogate for Mortality and Endpoint for Treatment**

Massimo Pinzani (IT)

03:00 - 04:00 PM SYMPOSIUM

04:00 - 04:30 PM COFFEE BREAK

04:30 - 06:00 PM SESSION 3: Advances in the Management of HCC

Chairs: Josep Llovet (ES-US) & Massimo Pinzani (IT)

04:30-04:45 **Overview of Guidelines of HCC management (EASL, AASLD, ESMO)**

Josep M Llovet (ES-US)

04:45-05:00 **Advances in the management of early/intermediate HCC**

Riccardo Lencioni (IT)

05:00-05:15 **Advances in the management of advanced HCC**

Lorenza Rimassa (IT)

05:15-05:30 **Emerging therapies**

David Pinato (UK)

05:30-06:00 **Panel discussion (moderator Massimo Pinzani)**

06:00 PM **CONCLUSION DAY 1**

Laurent Castera (FR) & Zobair Younossi (US)



TUESDAY, 20 JANUARY - MORNING

08:30 - 10:00 AM SESSION 4: MASLD Epidemiology, Economic Impact, and Risk

Stratification Using NITs

Chairs: Manolis Tsochatzis (UK) & Laurent Castera (FR)

08:30-08:45	<b>Epidemiology and financial impact of MASH</b> Zobair Younossi (US)
08:45-09:00	<b>NIT algorithms for identifying high risk patients with MASH</b> Jérôme Boursier (FR)
09:00-09:15	<b>Non-invasive tests for treatment response in MASH</b> Manolis Tsochatzis (UK)
09:15-09:30	<b>Pulling it all together: the use of NITs in clinical practice of MASH</b> Vincent Wong (HK)
09:30-10:00	<b>Panel discussion</b> (moderator Laurent Castera)

10:00 - 11:00 AM SYMPOSIUM

11:00 - 11:20 AM COFFEE BREAK

11:20 - 12:50 PM SESSION 5: MASLD Treatment

Chairs: Mazen Noureddin (US) & Vincent Wong (HK)

11:20-11:35	<b>Lifestyle modifications for patients with MASH</b> Shira Zelber-Sagi (IL)
11:35-11:50	<b>Treatment of MASH-Co Morbidities (type 2 diabetes)</b> Elisabetta Bugianesi (IT)
11:50-12:05	<b>Current treatment of MASH</b> Mazen Noureddin (US)
12:05-12:20	<b>Future treatments of MASH: What is in the pipeline?</b> Frank Tacke (DE)
12:20-12:50	<b>Panel Discussion</b> (moderator Vincent Wong, Michael Betel patient representative)



TUESDAY, 20 JANUARY - AFTERNOON

01:00 - 02:00 PM WORKSHOPS

**1 - Management of pruritus and fatigue for patients with PBC**

Andreas Kremer (CH) & Ana Lleo (IT)

**2 - How do I diagnose and manage portal hypertension in my clinic?**

Pierre-Emmanuel Rautou (FR) & Thomas Reiberger (AT)

**3 - What are the tips to implement diet and physical exercise in my practice?**

Sébastien Czernichow (FR) & Shira Zelber-Sagi (IL)

**4 - How to accurately estimate alcohol consumption over time in clinical practice?**

Sven Francque (BE) & Christophe Moreno (BE)

**5 - What are my preferred drugs to treat obesity or type 2 diabetes in a patient with MASLD?**

Cyrielle Caussy (FR) & Jean-François Gautier (FR)

02:00 - 02:30 PM COFFEE / DESSERTS

02:30 - 03:00 PM STATE OF THE ART

**Advances in hepatic encephalopathy**

Debbie Shawcross (UK)

03:00 - 04:00 PM SYMPOSIUM

04:00 - 04:30 PM COFFEE BREAK

04:30 - 06:00 PM SESSION 6: MetALD and ALD

Chairs: Maja Thiele (DK) & Christophe Moreno (BE)

04:30-04:45 **Update on diagnosis of MetALD** Maja Thiele (DK)

04:45-05:00 **The natural history of MetALD** Hannes Hagström (SE)

05:00-05:15 **Update on ALD** Ramon Bataller (ES)

05:15-05:30 **Pharmaceutical and non-pharmaceutical treatment for MetALD and ALD** Mark Thursz (UK)

05:30-06:00 **Panel discussion** (Christophe Moreno moderator)

06:00 PM **CONCLUSION DAY 2**

Laurent Castera (FR) & Zobair Younossi (US)



**WEDNESDAY, 21 JANUARY - MORNING**

**09:00 - 10:00 AM SESSION 7: R&D - The drug pipelines presented by sponsors  
(10 min each)**

Chairs: Laurent Castera (FR) & Zobair Younossi (US)

**10:00 - 10:30 AM COFFEE BREAK**

**10:30 - 11:45 AM SESSION 8: Current Optimal treatment and Future Innovations in PBC and PSC**

Chairs: Andreas Kremer (CH) & Ana Lleo (IT)

10:30-10:45	<b>How to treat and assess risk in a patient with PBC?</b> David Jones (UK)
10:45-11:00	<b>How to treat and monitor a patient with PSC?</b> Andreas Kremer (CH)
11:00-11:15	<b>Future treatment for PBC and PSC</b> Ana Lleo (IT)
11:15-11:45	<b>Panel Discussion</b>

**11:45 - 12:15 PM SPECIAL LECTURE**

**Screening for liver disease in the general population: the LiverScreen Story**

Pere Gines (ES)

**12:15 PM CONCLUSION DAY 3**

Laurent Castera (FR) & Zobair Younossi (US)



# Co-Chairs



**Laurent CASTERA, MD, PhD**

**FRANCE**

Professor of Hepatology, Head of the NASH/MASH Program

Department of Hepatology, Hôpital Beaujon, AP-HP

INSERM UMR 1149, Centre de Recherche sur l'Inflammation Paris Montmartre,  
Université Paris-Cité, Clichy, France



**Zobair M YOUNOSSI, MD, MPH**

**USA**

Professor and Chairman, the Global NASH/MASH Council

Center for Outcomes Research in Liver Disease

2411 1 Street, Washington DC 20023, USA





**Annalisa BERZIGOTTI, MD, PhD**  
**SWITZERLAND**

Full Professor of Clinical Hepatology at the University of Berne and Chief of Hepatology and Co-Director of the Department of Visceral Surgery and Medicine of the Inselspital, University Hospital of Berne



**Adrian GADANO, MD, PhD**  
**ARGENTINA**

Head of the Research Department at the Hospital Italiano de Buenos Aires



**Andreas KREMER, MD, PhD**  
**SWITZERLAND**

Head of Hepatology and Vice Director of the Department of Gastroenterology and Hepatology, University Hospital Zurich



**Pietro LAMPERTICO, MD, PhD**  
**ITALY**

Full Professor in the Gastroenterology, Director of the Gastroenterology and Hepatology Division, Head of the "A. M. e A. Migliavacca" Center for Liver Disease at the Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan



**Josep LLOVET, MD, PhD**  
**SPAIN**

Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York - USA)  
ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic Oncology at the Univ. of Barcelona



**Mazen NOUREDDIN, MD, MHSc**

**USA**

Professor of Medicine at the Lynda K. and David M. Underwood Center for Digestive Disorders J.C. Walter Jr. Transplant Center Sherrie & Alan Conover Center for Liver Disease & Transplantation at Houston Methodist Hospital



**Massimo PINZANI, MD, PhD**

**ITALY**

Emeritus Professor of Medicine at University College London (UCL) (UK)  
Scientific Director of UPMC (University of Pittsburgh Medical Center)-ISMETT IRCSS in Palermo



**Maja THIELE, MD, PhD**

**DENMARK**

Professor of Hepatology at Department of Gastroenterology and Hepatology, Odense University Hospital and University of Southern Denmark



**Manolis TSOCHATZIS, MD, MSc**

**UNITED KINGDOM**

Professor of Hepatology and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health, Royal Free Hospital in London



**Vincent WONG, MD**

**HONG KONG**

Mok Hing Yiu Professor of Medicine and head of the Division of Gastroenterology and Hepatology at The Chinese University of Hong Kong

## FACULTY

AGHEMO Alessio	LENS GARCÍA Sabela
ANGELI Paolo	LLEO Ana
ASSELAH Tarik	LLOVET Josep
BATALLER Ramon	MORENO Christophe
BERZIGOTTI Annalisa	NOUREDDIN Mazen
BETEL Michael	PAPATHEODIRIS George
BOURSIER Jérôme	PAWLOTSKY Jean-Michel
BRUNETTO Maurizia	PINATO David
BUGIANESI Elisabetta	PINZANI Massimo
BUTI Maria	RATZIU Vlad
CASTERA Laurent	RAUTOU Pierre-Emmanuel
CAUSSY Cyrielle	REIBERGER Thomas
CZERNICHOW Sébastien	RIMASSA Lorenza
CORNBERG Markus	SERFATY Lawrence
DUFOUR Jean-François	SHARMA Arya
DURAND François	SHAWCROSS Debbie
FRANCOZ Claire	TACKE Frank
FRANCQUE Sven	THABUT Dominique
GADANO Adrian	THIELE Maja
GAUTIER Jean-François	THURSZ Markus
GINES Pere	TSOCHATZIS Manolis
HAGSTRÖM Hannes	WONG Vincent
JONES David	YILMAZ Yusuf
KREMER Andreas	YOUNOSSI Zobair
LAMPERTICO Pietro	WILDING John
LENCIONI Riccardo	ZELBER SAGI Shira